Lunai Bioworks Inc. Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments
Lunai Bioworks Inc. (LNAI) reported Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments of $2.90 million for the 12-month period ending 2022-06-30, per its 10-K filed 2023-10-02.
Discontinued › Income Statement › Other Income
us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1 · last filed 2023-10-02
- Lunai Bioworks Inc. change in unrealized gain (loss) on fair value hedging instruments for the quarter ending 2022-06-30 was $7.97M.
- Lunai Bioworks Inc. change in unrealized gain (loss) on fair value hedging instruments for the quarter ending 2022-03-31 was -$2.08M.
- Lunai Bioworks Inc. change in unrealized gain (loss) on fair value hedging instruments for the quarter ending 2021-12-31 was -$167.25K, a 133.90% decline year-over-year.
- Lunai Bioworks Inc. change in unrealized gain (loss) on fair value hedging instruments for the quarter ending 2021-09-30 was -$2.82M, a 760.89% decline year-over-year.
- Lunai Bioworks Inc. change in unrealized gain (loss) on fair value hedging instruments for fiscal 2022 was $2.90M.
- Lunai Bioworks Inc. change in unrealized gain (loss) on fair value hedging instruments for fiscal 2021 was -$3.05M, a 1210.13% decline from fiscal 2020.
- Lunai Bioworks Inc. change in unrealized gain (loss) on fair value hedging instruments for fiscal 2020 was $274.57K.
| Period end | Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments 3 month | Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments 6 month | Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments 9 month | Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments 12 month |
|---|---|---|---|---|
| 2022-06-30 | $7.97M derived: 10-K 12 month − 10-Q 9 month · filed 2023-10-02 | $5.89M derived: sum of 2 quarters · filed 2023-10-02 | $5.72M derived: sum of 3 quarters · filed 2023-10-02 | $2.90M 10-K · filed 2023-10-02 |
| 2022-03-31 | -$2.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-05-12 | -$2.25M derived: sum of 2 quarters · filed 2023-05-12 | -$5.07M 10-Q · filed 2023-05-12 | -$8.16M derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | -$167.25K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-03-09 | -$2.99M 10-Q · filed 2023-03-09 | -$6.08M derived: sum of 3 quarters · filed 2023-03-09 | -$6.96M derived: sum of 4 quarters · filed 2023-03-09 |
| 2021-09-30 | -$2.82M 10-Q · filed 2023-03-07 | -$5.91M derived: sum of 2 quarters · filed 2023-03-07 | -$6.79M derived: sum of 3 quarters · filed 2023-03-07 | -$6.30M derived: sum of 4 quarters · filed 2023-03-07 |
| 2021-06-30 | -$3.09M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | -$3.97M derived: sum of 2 quarters · filed 2023-02-27 | -$3.48M derived: sum of 3 quarters · filed 2023-02-27 | -$3.05M 10-K · filed 2023-02-27 |
| 2021-03-31 | -$882.50K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-05-13 | -$389.09K derived: sum of 2 quarters · filed 2022-05-13 | $38.31K 10-Q · filed 2022-05-13 | |
| 2020-12-31 | $493.41K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-02-14 | $920.81K 10-Q · filed 2022-02-14 | ||
| 2020-09-30 | $427.40K 10-Q · filed 2021-11-15 | |||
| 2020-06-30 | $274.57K 10-K · filed 2021-09-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |